| Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer R Nishimura, T Osako, Y Okumura, M Hayashi, Y Toyozumi, N Arima Experimental and therapeutic medicine 1 (5), 747-754, 2010 | 250 | 2010 |
| Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis R Nishimura, T Osako, Y Okumura, M Hayashi, N Arima Breast cancer 17, 269-275, 2010 | 178 | 2010 |
| Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer M Hayashi, Y Yamamoto, M Ibusuki, S Fujiwara, S Yamamoto, S Tomita, ... Annals of surgical oncology 19, 3042-3049, 2012 | 119 | 2012 |
| Clinical significance of CYLD downregulation in breast cancer M Hayashi, H Jono, S Shinriki, T Nakamura, J Guo, A Sueta, M Tomiguchi, ... Breast cancer research and treatment 143, 447-457, 2014 | 97 | 2014 |
| Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes? A Sueta, Y Yamamoto, M Hayashi, S Yamamoto, T Inao, M Ibusuki, ... Surgery 155 (5), 927-935, 2014 | 84 | 2014 |
| A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells M Yamashita, S Kitano, H Aikawa, A Kuchiba, M Hayashi, N Yamamoto, ... Scientific reports 6 (1), 19772, 2016 | 55 | 2016 |
| Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary … M Tomiguchi, Y Yamamoto, M Yamamoto‐Ibusuki, L Goto‐Yamaguchi, ... Cancer science 107 (4), 491-498, 2016 | 52 | 2016 |
| Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression P Fu, M Ibusuki, Y Yamamoto, M Hayashi, K Murakami, S Zheng, H Iwase Breast cancer research and treatment 130, 307-317, 2011 | 49 | 2011 |
| Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development M Nishidate, M Hayashi, H Aikawa, K Tanaka, N Nakada, S Miura, S Ryu, ... Drug metabolism and pharmacokinetics 34 (4), 209-216, 2019 | 46 | 2019 |
| Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging H Aikawa, M Hayashi, S Ryu, M Yamashita, N Ohtsuka, M Nishidate, ... Scientific Reports 6 (1), 23749, 2016 | 41 | 2016 |
| Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy J Guo, S Shinriki, Y Su, T Nakamura, M Hayashi, Y Tsuda, Y Murakami, ... Oncotarget 5 (15), 6353, 2014 | 41 | 2014 |
| Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells T Nakamura, S Shinriki, H Jono, J Guo, M Ueda, M Hayashi, S Yamashita, ... Oncotarget 6 (2), 1008, 2015 | 36 | 2015 |
| C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients M Yamamoto-Ibusuki, Y Yamamoto, S Fujiwara, A Sueta, S Yamamoto, ... European Journal of Human Genetics 23 (7), 949-956, 2015 | 35 | 2015 |
| An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer A Sueta, Y Yamamoto, M Yamamoto-Ibusuki, M Hayashi, T Takeshita, ... PLoS One 9 (12), e116054, 2014 | 33 | 2014 |
| The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2-breast cancer S Fujiwara, M Yamamoto-Ibusuk, Y Yamamoto, S Yamamoto, ... Oncotarget 5 (11), 3919, 2014 | 32 | 2014 |
| Associations between elastography findings and clinicopathological factors in breast cancer M Hayashi, Y Yamamoto, A Sueta, M Tomiguchi, M Yamamoto-Ibusuki, ... Medicine 94 (50), 2015 | 27 | 2015 |
| Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging Y Tsubata, M Hayashi, R Tanino, H Aikawa, M Ohuchi, K Tamura, ... Scientific Reports 7 (1), 12622, 2017 | 20 | 2017 |
| Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer A Sueta, Y Yamamoto, M Yamamoto‑Ibusuki, M Hayashi, T Takeshita, ... International Journal of Oncology 46 (5), 2143-2153, 2015 | 19 | 2015 |
| Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma T Nakamura, S Shinriki, H Jono, M Ueda, M Nagata, J Guo, M Hayashi, ... FEBS letters 589 (2), 231-239, 2015 | 18 | 2015 |
| Population pharmacokinetics and adverse events of erlotinib in Japanese patients with non-small-cell lung cancer: impact of genetic polymorphisms in metabolizing enzymes and … C Endo-Tsukude, J Sasaki, S Saeki, N Iwamoto, M Inaba, S Ushijima, ... Biological and Pharmaceutical Bulletin 41 (1), 47-56, 2018 | 17 | 2018 |
